EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.
  • Home
  • About Us
    全部 Introduction Team Corporate Honors History
  • Pipeline
  • Technology
  • News
  • Job
  • Contact

  1. Home
  2. News

Special fund support for epidemic prevention scientific research and emergency production in Haidian District in 2020

2020-05-10 09:54:31 admin 25
     

1632623300898670.png

2020年11月我司获得中关村科学城管委会-2020年海淀区防疫科研攻关和应急生产专项资金支持100万元。


1632623300571579.jpg



  • Previous : In May 2020, the article on COVID-19 treatment antibody was published in Cold Spring Harbor of the United States
  • Next : The "patent authorization of bispecific antibody" was approved
  • News

为你推荐

  • Innovative bispecific antibody YKST02 officially started Phase I clinical trial
  • First in human (FIH) dosing completed for YKST02, a bispecific antibody drug for multiple myeloma immunotherapy in Phase I clinical trial
  • The IND application for YKST02 has been approved, and Phase I clinical trials will start soon
  • The signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held
  • NHL/ALL Immunotherapy Candidate Double Antibody YK012 Phase I Clinical Trial Completed First Subject Administration

版权所有 2017-2026 京ICP备17063430号

5 Kaituo Road, Haidian District, Beijing (Zhongguancun Bio-medicine Park) Room B306-308

18910977588

Powered by  MetInfo  7.5.0